Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
Submitted by
admin
on October 6, 2016 - 9:24am
Source:
Marketwatch
News Tags:
Alnylam
clinical trials
revusiran
Headline:
Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns
Do Not Allow Advertisers to Use My Personal information
